In the first five months of this year, 34 pediatric medications were approved for marketing; In March of this year, the new version of the National Medical Insurance Drug Catalogue was officially implemented, with new drugs covering 22 children's medication; In January of this year, the General Office of the National Health Commission issued a notice encouraging medical institutions to develop new technologies and methods that can flexibly adjust dosage for children's medication, strengthen standardized management and quality control of personalized medication... China has taken a series of measures to encourage the research and production of children's medication, and continuously improve the level of drug supply guarantee. According to data from the National Bureau of Statistics, at the end of 2022, the population aged 0-15 (including those under 16 years old) in China was 25.615 million, accounting for 18.1% of the total population. Compared with adult drugs, the research and development and production of children's drugs face problems such as late start, high difficulty, and weak foundation, which require joint efforts from medical institutions, research institutes, and pharmaceutical enterprises to solve. In January of this year, the General Office of the National Health Commission issued a notice on further strengthening the management of clinical medication in children, encouraging medical institutions to develop new technologies and methods that can flexibly adjust dosage for children's medication; In March, the new version of the National Medical Insurance Drug Catalogue was officially implemented, with new drugs covering 22 children's medication; In the first five months of this year, 34 children's drugs have been approved for sale, with a higher number of approvals than the same period last year... China has taken a series of measures to encourage the research and development and production of children's drugs, continuously improving the level of drug supply guarantee. Breaking through key technologies and filling the market gap "relying on medication and guessing dosage" has been a challenge faced by some children and parents when taking medication. Children are not the epitome of adults, and medication for children needs to be 'customized', "said Ni Xin, director of the National Children's Medical Center and director of Beijing Children's Hospital. Take Mercaptopurine, an important drug for the treatment of childhood acute lymphoblastic leukemia, as an example. At present, the only specification of Mercaptopurine sold on the market is 50mg tablets, about 1cm in diameter, which are adult tablets. When children take Mercaptopurine, the dose should be calculated according to the weight of kg, and the adult tablets should be cut or ground. It is inconvenient to use and the accuracy is not high. In order to solve this problem, the National Children's Medical Center and Beijing Children's Hospital took the lead in breaking through key technologies and developing an improved dosage form of Mercaptopurine that can be accurately measured. The tablet has a diameter of 2 to 3 millimeters and is the size of a grain of rice, making it easy for children to swallow. This achievement has been unveiled at the 2022 China International Service Trade Fair. "The varieties, dosage forms and specifications of drugs used by children in China are generally insufficient compared with those used by adults. About 45% of the Medication package insert in pediatric clinical drugs lack the use and dosage for children, which leads to a higher risk of medication errors for children than adults." Wang Xiaoling, director of the pharmacy department of Beijing Children's Hospital, said that integrating resources, breaking through a series of core key technologies, and reasonably conducting pediatric clinical research, It is the key to achieving efficient research and clinical transformation of pediatric medication. In recent years, Beijing Children's Hospital has been committed to the research and development of children's medication. Wang Xiaoling introduced that Beijing Children's Hospital has taken the lead in undertaking the major special project of "Children's Drug Varieties and Key Technology Research and Development" in the "13th Five Year Plan" for the creation of new drugs. It has collaborated with the research and development forces of 59 research institutes, universities, and enterprises nationwide to strengthen scientific and technological innovation and develop children's drugs. Currently, relevant information has been obtained